



Memorandum

Date: March 24, 2016

To: Genomics and Cell Characterization Core Facility (GC3F) Users

From: Doug Turnbull, Director Genomics and Cell Characterization Facility (GC3F) and GC3F Faculty Advisory Committee

A handwritten signature in black ink, appearing to read 'Brad Shelton', with a long horizontal line extending to the right.

CC: Brad Shelton, interim Vice President for Research and Innovation (VPRI)
Bill Cresko, Assoc. VP for Research, (VPRI)
Stacy Williams-Wright, Divisional Budget Director, (VPRI)
Melodi Jayne, Business Manager, Research Core Business Services, (RCB)

Re: FY 2017 sequencing rate adjustments – partial rate increase

The Genomics and Cell Characterization Core Facility (GC3F) set its sequencing rates after carefully reviewing costs and facility usage levels with the help of the Research Core Business Services (RCBS) team. The rates were recently reexamined by the GC3F and RCBS, and we determined that they are in line with RCBS financial projections and do not require radical change at this time.

However, Illumina, the company which is the sole source of the expensive sequencing reagents that are the largest component of the GC3F sequencing rates, recently announced an across the board price increase of 3% for all of their reagents which will go in to effect on April 1, 2015.

To account for this reagent price increase, the GC3F and its Faculty Advisory Committee consisting of Eric Johnson (chair), Matt Streisfeld, Kryn Stankunas, and Hans Dreyer recommend a 3% increase in the GC3F sequencing rates, effective July 1, 2016. These rate changes were brought to the Vice President for review and approval.

The adjusted sequencing rates are listed below on page two of this memo. If you have any questions regarding our new rates, please don't hesitate to send an email to htseq@molbio.uoregon.edu, or call 541-346-5170.